Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. PharmEasy Parent API Plans Rs 1,700 Cr NCD Issue To Repay Debt

PharmEasy Parent API Plans Rs 1,700 Cr NCD Issue To Repay Debt

16 Sept 2025

Add as preferred source
Key Takeaways

Debt reduction through Rs 1,700 crore NCDs, reduced collateral pledge, and narrowed FY24 losses strengthen PharmEasy’s investor confidence and IPO prospects.

Debt reduction through Rs 1,700 crore NCDs, reduced collateral pledge, and narrowed FY24 losses strengthen PharmEasy’s investor confidence and IPO prospects.

pharmeasy unlisted shares

API Holdings (Pharmeasy)

-8.09%

Expert Analysis

PharmEasy Parent API to Raise Rs 1,700 Cr via NCDs for Debt Repayment.

Expert Analysis:

  • Fundraising Plan: API Holdings, parent of PharmEasy, will raise Rs 1,700 crore through secured, redeemable NCDs, backed by Thyrocare shares as collateral.

  • Debt Repayment: Funds will repay existing NCD obligations worth Rs 1,545.4 crore, linked to an earlier Rs 1,820 crore issuance.

  • Stake Pledge Revision: Docon Technologies will pledge up to 61 per cent of its Thyrocare stake, reduced from 71.06 per cent earlier.

  • Strategic Moves: PharmEasy’s fundraising supports its debt-reduction strategy to boost liquidity and revive IPO plans, alongside leadership changes with Siddharth Shah becoming vice-chairman and Rahul Guha taking over as CEO.

  • Financial Performance: PharmEasy reported a consolidated loss of Rs 2,531 crore in FY24, nearly halving year-on-year losses through a 20 per cent expense cut.

Publisher:BW Disrupt